Pfizer Inc. Overview
Pro stress-test →Pfizer delivered solid financial performance in 2025, strengthening its foundation for future growth. The company is a leading global pharmaceutical and biotechnology firm focused on innovative medicines across oncology, vaccines, and rare diseases, among other therapeutic areas.
Strategic Profile
Pro stress-test →Pfizer's CEO identified 2026 as a key catalyst year for future growth through approximately 20 pivotal study starts, while maximizing the value of its $10 billion acquisition of obesity biotech Metsera. The company has identified six priority therapeutic areas—Oncology, Vaccines, Inflammation & Immunology, Rare Diseases, Internal Medicine, and Anti-Infectives—with oncology positioned as a key growth driver amplified by its 2023 acquisition of Seagen's antibody-drug conjugate portfolio.
Competitive Landscape
Pro stress-test →Pfizer competes in highly fragmented global pharmaceutical and biotech markets. Key competitors include Johnson & Johnson (vaccines, pharmaceuticals), Merck (oncology, vaccines), Moderna and BioNTech (mRNA vaccines), Novo Nordisk and Eli Lilly (GLP-1 therapies), and specialized players like Regeneron (immunology) and Amgen (biologics). Pfizer's competitive advantage rests on its diversified portfolio across multiple therapeutic areas, substantial R&D capabilities, and strategic M&A positioning in high-growth areas like obesity and oncology.
Industry Context
Pfizer Inc. operates in Pharmaceutical and Biotechnology.
Key facts
Founded: 1849 · Headquarters: New York, US · Employees: N/A · Revenue: $62.6B · Market cap: N/A